What Is Bone Density?

Bone density, formally expressed as bone mineral density (BMD), is a measure of the amount of mineral, primarily calcium and phosphate in the form of hydroxyapatite, contained in a given area or volume of bone tissue. It serves as the primary clinical indicator of bone strength and fracture risk, since bone stiffness and resistance to crack propagation scale with mineral content. BMD is quantified through imaging and physical measurement techniques that assess attenuation of X-rays or ultrasonic waves by mineralized bone tissue, producing values that can be compared to population reference standards. The field draws on medical physics, materials characterization, and clinical epidemiology.

Bone density declines naturally with age as osteoclast-mediated bone resorption outpaces osteoblast-driven bone formation, a process accelerated in women following menopause due to reduced estrogen levels and in both sexes by inactivity, nutritional deficiency, and certain medications. When BMD falls below defined thresholds, the skeleton becomes susceptible to fragility fractures from low-energy trauma, forming the basis of the clinical syndrome called osteoporosis.

Dual-Energy X-Ray Absorptiometry

Dual-energy X-ray absorptiometry (DXA) is the internationally accepted standard method for measuring BMD. A DXA scanner directs two X-ray beams of different energies, typically 70 keV and 140 keV, through the patient's body; the differential attenuation of the two beams by soft tissue and bone mineral allows software to extract areal BMD in grams per square centimeter at the lumbar spine, proximal femur, and distal radius. The examination delivers radiation doses of 1 to 10 microsieverts, roughly equivalent to one day of background radiation. As described in Dual-Energy X-Ray Absorptiometry in the StatPearls clinical reference published by the National Institutes of Health, the DXA result is expressed as a T-score, the number of standard deviations above or below the mean BMD of a young healthy reference population. The World Health Organization defines osteoporosis as a T-score of -2.5 or below, osteopenia (low bone mass) as a T-score between -1.0 and -2.5, and normal BMD as a T-score at or above -1.0.

Bone Mineral Density and Fracture Risk

BMD is a strong predictor of fracture probability but is not the only determinant of bone strength; bone microarchitecture, collagen matrix quality, and remodeling rate also contribute to fracture resistance. The FRAX algorithm, developed by the World Health Organization, integrates BMD with clinical risk factors, including age, sex, body mass index, and history of prior fracture, to estimate a patient's 10-year probability of a major osteoporotic fracture. A review of the role of DXA bone density scans in the diagnosis and treatment of osteoporosis describes how serial DXA measurements track the response to pharmacological treatment, with significant changes in BMD defined as a change exceeding the least significant change, a precision-derived threshold calculated from duplicate measurements on the same scanner.

Quantitative Computed Tomography and Ultrasound Methods

Quantitative computed tomography (QCT) measures true volumetric BMD in grams per cubic centimeter, distinguishing trabecular from cortical bone compartments and enabling three-dimensional finite element modeling of bone strength. Peripheral QCT (pQCT) and high-resolution pQCT extend this to the radius and tibia with higher resolution than central QCT, providing direct measures of bone microstructure. Quantitative ultrasound (QUS) devices, which are portable and radiation-free, assess bone at the calcaneus by measuring broadband ultrasound attenuation and speed of sound; as summarized in bone mineral density clinical relevance and quantitative assessment, QUS correlates with DXA-based fracture risk predictions and is used in screening programs where DXA access is limited.

Applications

Bone density measurement has applications in a range of fields, including:

• Clinical diagnosis of osteoporosis and osteopenia to guide pharmacological treatment decisions
• Fracture risk stratification in orthopedic and primary care settings
• Monitoring of bone loss in patients on long-term corticosteroid or anti-cancer therapies
• Orthopedic implant design, where BMD maps inform screw placement and fixation strength predictions
• Sports medicine and athlete health monitoring to detect low bone mass from energy deficiency